Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
9.73
-0.20 (-1.97%)
At close: Sep 10, 2025, 4:00 PM
9.67
-0.05 (-0.53%)
After-hours: Sep 10, 2025, 6:15 PM EDT
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $95.44M in the quarter ending June 30, 2025, with 29.33% growth. This brings the company's revenue in the last twelve months to $316.27M, up 26.66% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$316.27M
Revenue Growth
+26.66%
P/S Ratio
3.95
Revenue / Employee
$780,909
Employees
405
Market Cap
1.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DVAX News
- 14 days ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 20 days ago - Dynavax's shingles vaccine shows similar immune response to GSK's shot in study - Reuters
- 20 days ago - Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile - PRNewsWire
- 4 weeks ago - Dynavax Technologies: A Dip To Accumulate - Seeking Alpha
- 4 weeks ago - Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Dynavax Reports Second Quarter 2025 Financial Results - PRNewsWire
- 6 weeks ago - Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - PRNewsWire
- 3 months ago - Dynavax elects all four of its nominees after Deep Track proxy fight - Reuters